Marshall Wace
OTLK icon

Marshall Wace’s Outlook Therapeutics OTLK Stock Holding History

Marshall Wace’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-298,456
Closed -$472K – 3558
2025
Q4 		$472K Buy
+298,456
New +$477K ﹤0.01% 2259
2025
Q3 		– Sell
-25,564
Closed -$40.9K – 3270
2025
Q2 		$40.9K Buy
+25,564
New +$40.8K ﹤0.01% 2609
2022
Q2 		– Sell
-2,014
Closed -$71K – 3729
2022
Q1 		$71K Sell
2,014
-5,664
-74% -$177K ﹤0.01% 3225
2021
Q4 		$209K Buy
+7,678
New +$274K ﹤0.01% 3144
2021
Q2 		– Sell
-4,041
Closed -$182K – 2967
2021
Q1 		$182K Buy
+4,041
New +$155K ﹤0.01% 2287
2017
Q1 		– Sell
-1,636
Closed -$788K – 626
2016
Q4 		$788K Buy
1,636
+72
+5% +$40.3K 0.01% 786
2016
Q3 		$1.06M Hold
1,564
– – 0.01% 708
2016
Q2 		$851K Buy
+1,564
New +$933K 0.01% 744

Other funds holding OTLK

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GWM
Gilpin Wealth Management Denver, Colorado $126M AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
NMC
Nine Masts Capital Central, Hong Kong $693M AUM 31.93% 1-Year Est. Return
CCM
Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return

Marshall Wace's OTLK Position: Q1 2026 in Review

Marshall Wace sold out of Outlook Therapeutics (OTLK) in Q1 2026, closing a stake of 298,456 shares — an estimated $472K sold.

Marshall Wace first reported a position in OTLK in Q2 2016 and held it in 8 quarters. The position peaked at $1.06M in Q3 2016. 54 funds tracked by Wall St. Rank hold OTLK as of Q1 2026.

  • Marshall Wace reported no remaining Outlook Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Marshall Wace sold 298,456 Outlook Therapeutics shares in Q1 2026, an estimated $472K.
  • Marshall Wace first reported a position in Outlook Therapeutics in Q2 2016 and held it in 8 quarters.
  • Marshall Wace's Outlook Therapeutics position peaked at $1.06M in Q3 2016.
  • 54 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.